Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Haematologica

Topics

Physics

Cancer Oncology

Medicine

Internal Medicine

Hematology

Show all topics

DOI

10.3324/haematol.2024.285534

License

CC-BY-NC

Other Formats

PDF